-
公开(公告)号：EP3774862A1
公开(公告)日：2021-02-17
申请号：EP19724915.4
申请日：2019-04-05
发明人： THENNATI, Rajamannar , CHATURVEDI, Nishith , BURADE, Vinod Sampatrao , SHAHI, Pradeep Dinesh , NATARAJAN, Muthukumaran , NAGARAJA, Ravishankara Madavati , ZALAWADIA, Rishit Mansukhlal , PANDYA, Kunal , PATEL, Brijeshkumar , JOSHI, Dhiren Rameshchandra , SONI, Krunal Harishbhai , TIWARI, Abhishek , PATEL, Vipulkumar Shankarbhai
IPC分类号： C07K14/605 , A61K38/26
-
公开(公告)号：EP4364751A3
公开(公告)日：2024-06-26
申请号：EP24161843.8
申请日：2019-04-05
发明人： THENNATI, Rajamannar , CHATURVEDI, Nishith , BURADE, Vinod Sampatrao , SHAHI, Pradeep Dinesh , NATARAJAN, Muthukumaran , NAGARAJA, Ravishankara Madavati , ZALAWADIA, Rishit Mansukhlal , PANDYA, Kunal , PATEL, Brijeshkumar , JOSHI, Dhiren Rameshchandra , SONI, Krunal Harishbhai , TIWARI, Abhishek , PATEL, Vipulkumar Shankarbhai
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
-
公开(公告)号：EP4364751A2
公开(公告)日：2024-05-08
申请号：EP24161843.8
申请日：2019-04-05
发明人： THENNATI, Rajamannar , CHATURVEDI, Nishith , BURADE, Vinod Sampatrao , SHAHI, Pradeep Dinesh , NATARAJAN, Muthukumaran , NAGARAJA, Ravishankara Madavati , ZALAWADIA, Rishit Mansukhlal , PANDYA, Kunal , PATEL, Brijeshkumar , JOSHI, Dhiren Rameshchandra , SONI, Krunal Harishbhai , TIWARI, Abhishek , PATEL, Vipulkumar Shankarbhai
IPC分类号： A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
-
公开(公告)号：EP4122954A1
公开(公告)日：2023-01-25
申请号：EP22177403.7
申请日：2019-04-05
发明人： THENNATI, Rajamannar , CHATURVEDI, Nishith , BURADE, Vinod Sampatrao , SHAHI, Pradeep Dinesh , NATARAJAN, Muthukumaran , NAGARAJA, Ravishankara Madavati , ZALAWADIA, Rishit Mansukhlal , PANDYA, Kunal , PATEL, Brijeshkumar , JOSHI, Dhiren Rameshchandra , SONI, Krunal Harishbhai , TIWARI, Abhishek , PATEL, Vipulkumar Shankarbhai
IPC分类号： C07K14/605 , A61K38/26
摘要： The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
